Search

Displaying results 3731 - 3740 of 8974 in total
  1. Drug

    Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB16923
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  2. Drug

    Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB18750
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  3. Drug

    Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB22669
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  4. Drug

    Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB22671
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  5. Drug

    Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB31654
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  6. Drug

    Cocarboxylase

    go.drugbank.com/drugs/DB01987
    ApprovedInvestigational

    The coenzyme form of Vitamin B1 present in many animal tissues. It is a required intermediate in the pyruvate dehydrogenase complex and the ketoglutarate dehydrogenase complex.

    Mixtures: CERNEVIT FOR INJECTION, Cernevit, Lyophilisate for Reconstitution
  7. Drug

    Iomeprol

    go.drugbank.com/drugs/DB11705
    ApprovedInvestigational

    Iomeprol is a tri-iodinated, non-ionic radiographic contrast agent for intraarterial or intravenous use.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    CoviGlobulin

    go.drugbank.com/drugs/DB15747
    Experimental

    Current applications of antibodies include, but are not limited to, targeting cancer, inflammatory diseases, organ transplantation, cardiovascular disease, infection, respiratory disease, and ophthalmologic … CoviGlobulin, a rabbit polyclonal antibody, was specifically designed as a potential therapy for COVID-19.

  9. Drug

    ISS-1018

    go.drugbank.com/drugs/DB05463
    Investigational

    ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults. … ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha

  10. Drug

    Pirfenidone

    go.drugbank.com/drugs/DB04951
    ApprovedInvestigational

    [A251370] It is an antifibrotic agent with anti-inflammatory and antioxidant properties [A251370] that is used to treat idiopathic pulmonary fibrosis (IPF),[L26801] which is a chronic, progressive form … [A251365] The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.[A251165]